Skip to main content

Anticoagulation Management in Patients Undergoing Gastric Bypass Procedures

  • Chapter
  • First Online:
Oral Anticoagulation Therapy
  • 1231 Accesses

Abstract

Patients undergoing gastric bypass surgery are at high risk for venous thromboembolic events, especially those with a history of prior events. Limited clinical studies are available to evaluate safe anticoagulant use in the periprocedural time period so close monitoring is essential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. The American Society of Metabolic and Bariatric Surgery Clinical Issues Committee. ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. Surg Obes Relat Dis. 2013;9:493–7.

    Article  Google Scholar 

  2. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e326S–50S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S–43S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Vaziri K, Bhanot P, Hungness ES, Morasch MD, Prystowsky JB, Nagle AP. Retrievable inferior vena cava filters in high-risk patients undergoing bariatric surgery. Surg Endosc. 2009;23(10):2203–7.

    Article  PubMed  Google Scholar 

  5. Vaziri K, Devin-Watson J, Harper AP, et al. Prophylactic inferior vena cava filters in high-risk bariatric surgery. Obes Surg. 2011;21:1580–4.

    Article  PubMed  Google Scholar 

  6. Rowland SP, Dharmarajah B, Moore HM, et al. Inferior vena cava filters for prevention of venous thromboembolism in obese patients undergoing bariatric surgery: a systematic review. Ann Surg. 2015;261:35–45.

    Article  PubMed  Google Scholar 

  7. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.

    Article  PubMed  Google Scholar 

  8. Prystowsky JB, Morasch MD, Eskandari MK, Hungness ES, Nagle AP. Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. Surgery. 2005;138:759–65.

    Article  PubMed  Google Scholar 

  9. Froehling DA, Daniels PR, Mauck KF, Collazo-Clavell ML, Ashrani AA, Sarr MG, Petterson TM, Bailey KR, Heit JA. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. Obes Surg. 2013;23(11):1874–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Irwin AN, McCool KH, Delate T, Witt DM. Assessment of warfarin dosing requirements after bariatric surgery in patients requiring long-term warfarin therapy. Pharmacotherapy. 2013;33(11):1175–83.

    Article  CAS  PubMed  Google Scholar 

  11. Chan LN. Warfarin dosing changes after bariatric surgery: implications on the mechanism for altered dose requirements and safety concerns—an alternate viewpoint. Pharmacotherapy. 2014;34(4):e26–9.

    Article  CAS  PubMed  Google Scholar 

  12. Steffen KJ, Wonderlich JA, Erickson AL, Strawsell H, Mitchell JE, Crosby RD. Comparison of warfarin dosages and international normalized ratios before and after roux-en-y gastric bypass surgery. Pharmacotherapy. 2015;35(9):876–80.

    Article  CAS  PubMed  Google Scholar 

  13. Lachant DJ, Uraizee I, Gupta R, Pedulla R. Novel oral anticoagulants after gastric bypass surgery: caveat emptor. Int J Case Rep Imag. 2013;4(11):663–5.

    Article  Google Scholar 

  14. Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis. 2013;36(4):533–5.

    Article  PubMed  Google Scholar 

  15. APB study: Apixaban pharmacokinetics in bariatric patients. https://clinicaltrials.gov/ct2/show/NCT02406885. Accessed 4 Apr 2016.

  16. Domienik-Karlowicz J, Pruszczyk P. The use of anticoagulants in morbidly obese patients. Cardiol J. 2016;23(1):12–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian Cryder PharmD, BCACP .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Cryder, B. (2017). Anticoagulation Management in Patients Undergoing Gastric Bypass Procedures. In: Kiser, K. (eds) Oral Anticoagulation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-54643-8_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-54643-8_39

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-54641-4

  • Online ISBN: 978-3-319-54643-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics